国家医保局发布药代篡改检测报告骗保案例；礼来市值突破万亿美元

Group 1 - The National Healthcare Security Administration of China disclosed a case of fraud involving a pharmaceutical representative who altered genetic testing reports to meet personal sales targets, leading to the use of targeted cancer drugs in patients who did not meet the necessary criteria, resulting in losses to the medical insurance fund [1] - The case serves as a warning about the importance of adhering to drug indications and genetic mutation conditions to ensure effective targeted therapy, emphasizing that legal consequences are in place for violations [1] Group 2 - Hainan Haiyao announced that its stock experienced an abnormal trading fluctuation, with a cumulative closing price increase of over 20% over two consecutive trading days [2] - The company confirmed that there were no violations of information disclosure regulations, suggesting that investors should monitor official information disclosure channels for rational investment decisions [2] Group 3 - Eli Lilly became the first pharmaceutical company to surpass a market capitalization of $1 trillion, achieving this milestone on November 21 [3] - The company's weight loss drug, Zepbound, which is set to launch at the end of 2023, has already captured a significant share of new obesity drug prescriptions, surpassing Novo Nordisk's Wegovy [3] - This achievement marks a shift in the "trillion-dollar club," traditionally dominated by tech giants, highlighting Eli Lilly's emergence as a leader in the metabolic health sector [3]